Top Markets
Coin of the day
ObsEva S.A. ObsEva S.A.

ObsEva S.A.

OBSN
Kedudukan dalam Saham #40302
ObsEva S.A. is a biopharmaceutical company focused on developing and... ObsEva S.A. is a biopharmaceutical company focused on developing and commercializing groundbreaking therapies for women facing challenges in reproductive health and pregnancy. Its product pipeline includes Linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist currently in Phase III clinical trials. Linzagolix is being evaluated for its efficacy in treating pain associated with endometriosis and heavy menstrual bleeding linked to uterine fibroids in pre-menopausal women. The firm is also progressing with Ebopiprant, an oral and selective prostaglandin F2a (PGF2a) receptor antagonist, which is in Phase II clinical trials as a once-daily treatment for preterm labor occurring between 24 and 34 weeks of gestational age. Additionally, ObsEva is developing Nolasiban, an oral oxytocin receptor antagonist in Phase I clinical trials, aimed at enhancing clinical pregnancy and live birth rates for women undergoing in vitro fertilization. ObsEva S.A. was founded in 2012 and maintains its headquarters in Geneva, Switzerland.
Harga Saham
$0.00156067
Disegerakkan terakhir: 2024-05-03
Modal Pasaran
$182.87K
Perubahan (1 hari)
-72.69%
Perubahan (1 tahun)
0.00%
Negara
CH
Perdagangan ObsEva S.A. (OBSN)

Kategori

Sejarah dividen untuk ObsEva S.A. (OBSN)
ObsEva S.A. (simbol saham: OBSN) telah membuat sejumlah 0 pembayaran dividen.
Jumlah semua dividen (disesuaikan untuk pemecahan saham): 0.00
Hasil dividen (TTM): 0
Pembayaran dividen untuk ObsEva S.A. (OBSN) dari 2026 hingga 2026
Pembayaran dividen tahunan
Tahun Dividen (diselaraskan untuk pemecahan saham) Ubah
Tidak cukup data untuk tarikh yang disediakan.
Senarai semua pembayaran dividen
Tahun Dividen Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pembayaran dividen untuk syarikat serupa atau pesaing
Syarikat Jumlah pembayaran dividen Negara
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
29.00%
BE